Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda

Loading...
Thumbnail Image

Authors

Nansera, Denis
Bajunirwe, Francis
Elyanu, P.
Asiimwe, Caroline
Amanyire, Gideon
Graziano, F. M.

Journal Title

Journal ISSN

Volume Title

Publisher

The International Journal of Tuberculosis and Lung Disease

Abstract

BACKGROUND: We describe the presentation and outcome of care among patients with tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection from a prospective observational cohort in Uganda. METHODS: We analysed basic demographics, CD4+ counts, time of initiating antiretroviral therapy (ART), clinical and haematological parameters and outcome of care of 386 patients enrolled between February 2007 and March 2010. RESULTS: At presentation, 56.7% of the patients were sputum-positive, 89.9% had new TB infection, 62.7% had wasting, 78.7% were anaemic, 72.1% had a CD4+ count of <200 cells/mm3, 20.2% had pneumonia, 50.3% had oral thrush and 1.3% had Kaposi’s sarcoma. Patients developing TB within 3 months of starting ART were less likely to have wasting, to be anaemic or to have a CD4+ count of <100 cells/mm3. The cure, default and death rates were respectively 54.3%, 24% and 16%. At 8 months, 53 (13.7%) were confirmed dead, 119 (30.8%) were lost to follow-up, 28 (7.3%) were transferred out and 1 (0.3%) had treatment failure. Mortality and loss to follow-up were associated with failure to start ART and having a CD4+ count of <200 cells/mm3. CONCLUSION: In Uganda, TB-HIV patients present with severe immune suppression and are at increased risk of death and loss to follow-up, particularly those not on ART. There is need for early identification and improved follow-up of TB-HIV co-infected patients

Description

Citation

Nansera, D., Bajunirwe, F., Elyanu, P., Asiimwe, C., Amanyire, G., & Graziano, F. M. (2012). Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda. The International journal of tuberculosis and lung disease, 16(10), 1371-1376.

Endorsement

Review

Supplemented By

Referenced By